InvestSMART

Acrux Limited (ASX: ACR) - Announcements

- Current share price for ACR : $0.011

ASX company news and announcements for Acrux Limited (ACR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Acrux Limited (ACR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Acrux Limited (ACR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Acrux Limited (ACR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$6 Proposed issue of securities - ACR 5 Dec 2024 10:01AM $0.045 $0.011 fallen by 75.56%
$6 Share Placement successfully concluded and SPP launched 5 Dec 2024 10:01AM $0.045 $0.011 fallen by 75.56%
$6 FDA Approval - Nitroglycerin Ointment 4 Dec 2024 8:34AM $0.045 $0.011 fallen by 75.56%
$6 Trading Halt 3 Dec 2024 9:08AM $0.045 $0.011 fallen by 75.56%
$6 Results of Meeting 21 Nov 2024 2:06PM $0.045 $0.011 fallen by 75.56%
$6 AGM Presentation 21 Nov 2024 8:30AM $0.045 $0.011 fallen by 75.56%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 31 Oct 2024 8:29AM $0.053 $0.011 fallen by 79.25%
$6 Notice of Annual General Meeting/Proxy Form 15 Oct 2024 9:51AM $0.058 $0.011 fallen by 81.03%
$6 FY24 R&D Tax Incentive rebate received 2 Oct 2024 8:53AM $0.053 $0.011 fallen by 79.25%
$6 ASX Small and Mid Cap Conference presentation 24 Sep 2024 8:24AM $0.053 $0.011 fallen by 79.25%
$6 Investor Webinar Information - FY24 Results 29 Aug 2024 10:03AM $0.060 $0.011 fallen by 81.67%
$6 FY24 Full Year Results - Investor Presentation 29 Aug 2024 10:02AM $0.060 $0.011 fallen by 81.67%
$6 Appendix 4G and Corporate Governance Statement FY24 29 Aug 2024 10:00AM $0.060 $0.011 fallen by 81.67%
$6 Appendix 4E and FY24 Full Year Statutory Accounts 29 Aug 2024 9:59AM $0.060 $0.011 fallen by 81.67%
$6 FDA Approval received for Dapsone Gel, 7.5% 27 Aug 2024 9:27AM $0.060 $0.011 fallen by 81.67%
$6 Quarterly Activities Report and Appendix 4C - June 2024 26 Jul 2024 8:57AM $0.069 $0.011 fallen by 84.06%
$6 Acrux presentation to Bioshares, 18th Biotech Summit 15 Jul 2024 8:59AM $0.065 $0.011 fallen by 83.08%
$6 RDTI funding facility secured 28 Jun 2024 9:28AM $0.071 $0.011 fallen by 84.51%
$6 Acrux presentation at Hidden Gems in Lifesciences Forum 13 Jun 2024 9:36AM $0.083 $0.011 fallen by 86.75%
$6 Quarterly Activities and Appendix 4C, reissued 30 Apr 2024 11:08AM $0.070 $0.011 fallen by 84.29%
$6 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 9:48AM $0.061 $0.011 fallen by 81.97%
$6 Launch of Dapsone 5%, Gel in the United States 3 Apr 2024 8:34AM $0.047 $0.011 fallen by 76.60%
$6 Appendix 3Y Dobinson 5 Mar 2024 3:12PM $0.053 $0.011 fallen by 79.25%
$6 Appendix 3Y Brumley 5 Mar 2024 3:11PM $0.053 $0.011 fallen by 79.25%
$6 Application for quotation of securities - ACR 5 Mar 2024 3:09PM $0.053 $0.011 fallen by 79.25%

126 - 150 of 692 results

Page 6 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.